Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-23T20:48:42.869Z Has data issue: false hasContentIssue false
  • English
  • Français

Concurrent Outbreak of Multidrug-Resistant and Susceptible Subclones of Acinetobacter baumannii Affecting Different Wards of a Single Hospital

Published online by Cambridge University Press:  21 June 2016

Joel N. Maslow ,
Thomas Glaze ,
Pamela Adams  and
Max Lataillade
Joel N. Maslow*
Affiliation:
Section of Infectious Diseases, VA Medical Center, and the Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania
Thomas Glaze
Affiliation:
Section of Infectious Diseases, VA Medical Center, and the Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania
Pamela Adams
Affiliation:
Section of Infectious Diseases, VA Medical Center, and the Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania
Max Lataillade
Affiliation:
Section of Infectious Diseases, VA Medical Center, and the Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania
*
ACOS for Research, VA Medical Center (151), University and Woodland Avenues, Philadelphia, PA 19104Joel.Maslow@med.va.gov
Get access Rights & Permissions [Opens in a new window]

Abstract

Background and Objective:

Acinetobacter baumannii has emerged as an opportunistic pathogen among acutely ill patients, especially those with thermal injury. A prospective 8-month study was conducted to describe the clinical and molecular epidemiology of multidrug-resistant A. baumannii affecting a single hospital.

Methods:

Univariate analysis comparing Smal macrorestriction patterns of A. baumannii generated by pulsed-field gel electrophoresis (PFGE) versus clinical and demographic risk factors.

Results:

A total of 200 isolates from 76 patients were collected, of which 185 isolates from 76 patients were analyzed by PFGE. A total of 17 distinct PFGE clonal types were identified. One clonal type (strain A) represented 129 isolates from 49 patients. A group of related clonal types (strain A variants) were identified as 40 isolates from 20 patients. The only risk factor other than geographic location associated with the presence of strain A was prior treatment with antibiotics active against gram-negative bacteria (P = .0015). The two clonal types differed in antibiotic resistance profiles: 25% of strain A isolates, the dominant strain in the burn unit, were susceptible to at least one antibiotic tested. In contrast, approximately 80% of the other strain types were susceptible to at least one antibiotic and were cultured from patients admitted elsewhere in the hospital. No combination of antibiotics was observed to yield additive or synergistic activity.

Conclusion:

Clonally related strains of Acinetobacter that differ in susceptibility patterns may coexist within a single hospital, dependent on the selective pressure related to antibiotic exposure.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 26 , Issue 1 , January 2005 , pp. 69 - 75
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Husni, RN, Goldstein, LS, Arroliga, AC, et al.Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999;115:1378–1382.Google Scholar
2.Wisplingboff, H, Perbix, W, Seifert, H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case control study of adult burn patients. Clin Infect Dis 1999;28:59–66.CrossRefGoogle Scholar
3.Wong, TH, Tan, BH, Ling, ML, Song, C. Multi-resistant Acinetobacter baumannii on a burns unit. Burns 2002;28:349–357.Google Scholar
4.Simor, AE, Lee, M, Vearncombe, M, et al.An outbreak due to multire-sistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol 2002;23:261–267.CrossRefGoogle Scholar
5.Roberts, SA, Findlay, R, Lang, SD. Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in an intensive care burns unit J Hosp Infect 2001;48:228–232.Google Scholar
6.Levin, AS, Gobara, S, Mendes, CM, Cursino, MR, Sinto, S. Environmental contamination by multidrug-resistant Acinetobacter baumannii in an intensive care unit. Infect Control Hosp Epidemiol 2001;22:717–720.Google Scholar
7.Garcia-Garmendia, JL, Ortiz-Leyba, C, Garnacho-Montero, J, Jimenez-Jimenez, FJ, Monterrubio-Villar, J, Gili-Miner, M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999;27:1794–1799.Google Scholar
8.Lesseva, M. Central venous catheter-related bacteraemia in burn patients. Scand J Infect Dis 1998;30:585–589.Google Scholar
9.Swartz, KA, Wilson, SJ. Attributable mortality of carbapenem-resistant Acinetobacter baumannii at a public teaching hospital. Presented at the 13th Annual Meeting of the Society for Healthcare Epidemiology of America; April 5-8, 2003; Arlington, VA.Google Scholar
10.Paavilainen, T, Alanen, M, Makela, M, et al.Infrequent isolation of multiresistant Acinetobacter baumannii from the staff tending a colonized patient with severe burns. Infect Control Hosp Epidemiol 2001;22:388–391.Google Scholar
11.Neely, AN, Maley, MP, Warden, GD. Computer keyboards as reservoirs for Acinetobacter baumannii in a burn hospital. Clin Infect Dis 1999;29:1358–1360.CrossRefGoogle Scholar
12.Jellison, TK, McKinnon, PS, Rybak, MJ. Epidemiology, resistance, and outcome of Acinetobacter baumannii bacteremia treated with imipen-em-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001;21:142–148.Google Scholar
13.Levin, AS. Multiresistant Acinetobacter infections: a role of sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002;8:144–153.Google Scholar
14.Levin, AS, Barone, AA, Penco, J, et al.Intravenous Colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008–1011.Google Scholar
15.Montero, A, Ariza, J, Corbella, X, et al.Efficacy of Colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946–1952.Google Scholar
16.Saugar, JM, Alarcon, T, Lopez-Hernandez, S, Lopez-Brea, M, Andreu, D, Rivas, L. Activities of polymyxin B and cecropin A-, mellitin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:875–878.CrossRefGoogle Scholar
17.Nikolaidis, P, Metallidis, S, Kollaras, P, Tsona, A, Loumedaki, E, Tsaousoglu, D. In-vitro activity of clinafloxacin compared to ciprofloxacin against Acinetobacter baumannii strains isolated from intensive care unit patients. J Chemother 2002;14:234–236.Google Scholar
18.Fung-Tome, JC, Gradelski, E, Valera, L, Huczko, E, Bonner, DP. Synergistic activity of the novel des-fluoro(6) quinolone garenfloxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Int J Antimicrob Agents 2002;20:57–60.Google Scholar
19.Garnacho-Montero, J, Ortiz-Leyba, C, Jimenez-Jimenez, FJ, et al.Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous Colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111–1118.Google Scholar
20.Cawley, MJ, Suh, C, Lee, S, Ackerman, BH. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy 2002;22:527–532.Google Scholar
21.Clark, RB, Reeves, MW, Young, CY, Waegel, A, Haith, LR, Patton, ML. Outbreak of multiple antibiotic-resistant Acinetobacter baumannii in a burn unit: association with one predominate strain. Presented at the General Meeting of the American Society of Microbiology; May 26-30, 1992; Atlanta, GA.Google Scholar
22.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002. Approved standard M100-S12.Google Scholar
23.Maslow, JN, Slutsky, AM, Arbeit, RD. Application of pulsed field gel electrophoresis to molecular epidemiology. In: Persing, DH, Smith, TF, Tenover, FC, White, TJ, eds. Diagnostic Molecular Microbiology: Principles and Applications. Washington, DC: American Society of Microbiology; 1993:563–572.Google Scholar
24.Kleinbaum, DG, Kupper, LL, Morganstern, H. Epidemiologie Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold; 1982.Google Scholar
25.Ackerman, BH, Ross, J, Tofte, RW, Rotschafer, JC. Effect of decreased renal function on the pharmacokinetics of ceftazidime. Antimicrob Agents Chemother 1984;25:785–786.Google Scholar
26.Joly-Guillou, M-L, Deere, D, Herrmann, JL, Bourdelier, E, Bergogne-Berezi, E. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 1995;36:619–629.CrossRefGoogle ScholarPubMed
27.Mokaddas, E, Rotimi, VO, Sanyal, SC. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients. J Chemother 1998;10:208–214.Google Scholar